BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued on Friday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

BIOL stock opened at $0.01 on Friday. BIOLASE has a 52-week low of $0.02 and a 52-week high of $1.94. The firm has a market cap of $287,300.20, a P/E ratio of 0.00 and a beta of 0.67. The company’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.03.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.